NasdaqGM - Delayed Quote USD

Cerus Corporation (CERS)

Compare
1.7400 -0.0600 (-3.33%)
At close: June 14 at 4:00 PM EDT
1.7400 0.00 (0.00%)
After hours: June 14 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. William M. Greenman President, CEO & Director 1.04M -- 1967
Mr. Kevin D. Green VP of Finance & CFO 607.53k -- 1972
Mr. Vivek K. Jayaraman Chief Operating Officer 696.68k -- 1975
Ms. Chrystal Jensen Chief Legal Officer & General Counsel 571.49k -- 1971
Dr. Richard J. Benjamin MBChB, Ph.D. Chief Medical Officer 603.68k -- 1960
Dr. Laurence M. Corash Co-Founder & Chief Scientific Officer 697.77k 191.79k 1944
Ms. Lori L. Roll VP of Administration & Corporate Secretary -- -- --
Mr. Matthew M. Notarianni Senior Director of Investor Relations -- -- --
Lainie Corten Vice President of Global Marketing -- -- --
Ms. Alicia Goodman Chief Human Resources Officer -- -- --

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000 https://www.cerus.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
625

Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of June 1, 2024 is 4. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 7; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 31, 2024 at 10:59 AM UTC - August 5, 2024 at 12:00 PM UTC

Cerus Corporation Earnings Date

Recent Events

June 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 5, 2024 at 3:00 PM UTC

Annual Shareholders Meeting

May 31, 2024 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 2, 2024 at 8:30 PM UTC

Q1 2024 Earnings Call

May 2, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 26, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 19, 2024 at 1:00 PM UTC

to Host Investor Call for ReCePI Results

March 19, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 5, 2024 at 9:30 PM UTC

Q4 2023 Earnings Call

March 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers